一种芬太尼疫苗在2026年进入人类试验阶段,训练免疫系统,以阻止药物影响和防止剂量过量。 A fentanyl vaccine enters human trials in 2026, training the immune system to block the drug’s effects and prevent overdoses.

2026年将开始人类临床试验, 目的是通过训练免疫系统在芬太尼进入大脑之前阻止其影响, A first-of-its-kind fentanyl vaccine is set to begin human clinical trials in 2026, aiming to prevent overdoses by training the immune system to block fentanyl’s effects before it reaches the brain. 由ARMR科学公司和休斯顿大学开发的疫苗使用合成芬太尼碎片和免疫刺激剂刺激抗体生产。 Developed by ARMR Sciences and the University of Houston, the vaccine uses a synthetic fentanyl fragment and immune-boosting agents to stimulate antibody production. 与Naloxone不同,Naloxone在发生过量后逆转过量剂量,这种预防办法可以降低死亡率,特别是因为芬太尼越来越多地出现在其他药物中,而使用者却不知情。 Unlike naloxone, which reverses overdoses after they occur, this preventive approach could reduce fatalities, especially as fentanyl is increasingly found in other drugs without users’ knowledge. 审判将评估阻碍芬太尼影响的安全性和效果。 Trials will evaluate safety and effectiveness in blocking fentanyl’s impact.